On Oct. 12, 2010, Bristol-Myers Squibb Company announced it had completed its acquisition of ZymoGenetics. Bristol-Myers Squibb initiated on September 10, 2010, a cash tender offer to purchase all outstanding shares of common stock of ZymoGenetics for $9.75 per share.

The transaction had an aggregate purchase price of $885 million.